Inorganic Nanoparticle Protein Aggregate Standards
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing standards for detecting protein aggregates in protein misfolding diseases are limited in their use due to issues such as inhomogeneous size distribution, instability, and limited adaptability, which restricts their application across different diseases and prolonged use.
Innovation Solution
A method involving the production of inorganic nanoparticles, such as silica or gold, with precisely controlled sizes and surface functionalization to mimic protein aggregates, allowing for the binding of specific epitope regions, thereby creating a universal standard for detecting protein misfolding diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If polymer standards with polypeptide sequences identical or homologous to endogenous proteins are used, then the standards can determine the actual number of pathogenic aggregates, but the standards have limited use and lack universal applicability
Solution Approach 1:
The patent creates standardized protein aggregates with defined sizes and compositions that serve as universal reference copies. These standardized aggregates (e.g., Aβ42 aggregates with specific oligomer sizes) can be produced in controlled quantities and used as calibration standards across different diseases and detection methods, replacing the need for disease-specific polymer standards
Solution Approach 2:
The patent develops a platform technology where standardized protein aggregates can serve multiple functions: as calibration standards for different immunoassays, as reference materials for different disease types, and as controls for various detection platforms. The standardized aggregates with defined characteristics (size, composition, stability) provide universal applicability while maintaining the ability to accurately quantify pathogenic aggregates
2Reliability
If aggregate standards are produced from recombinant or synthetic Aβ with induced aggregation, then the various aggregate species can be purified and stabilized, but the standards have limited use and restricted application
Solution Approach 1:
The patent systematically varies key parameters of the standardized aggregates including size (oligomer composition), protein sequence (different Aβ variants), and physical-chemical properties (solubility, stability). By controlling these parameters during production, the patent creates a family of standardized aggregates that can be selected and adapted for different disease types and detection requirements while maintaining reliability and stability
Solution Approach 2:
The patent produces controlled copies of pathogenic aggregates with defined characteristics rather than relying on naturally occurring variable aggregates. These synthesized standard aggregates serve as reliable reference materials that can be uniformly produced and stored, providing both stability for long-term use and adaptability through systematic variation of copy parameters
3Measurement precision
If existing standards for determining pathological protein aggregates are used, then quantification is possible, but the standards have limited use and cannot be universally applied over long terms
Solution Approach 1:
The patent creates stable, defined copies of protein aggregates that serve as permanent reference standards. These standardized aggregates with controlled composition and structure can be produced in bulk, stored long-term with maintained stability, and repeatedly used for quantification without degradation, replacing existing standards with limited shelf-life
Solution Approach 2:
The patent optimizes physical-chemical parameters of the standardized aggregates (solubility, stability, resistance to degradation) to ensure long-term usability. By controlling aggregation state, protein sequence, and environmental stability parameters, the patent creates standards that maintain their quantification capability over extended periods and can be stored under various conditions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method produces stable, universally applicable standards with precise size and epitope distribution, enhancing the detection of protein aggregates across various diseases and extending their usability over time.
Implementation Method 1
forming free amino groups or free carboxyl groups on the surface of the nanoparticle (for functionalizing the nanoparticle surface into an amine- or carboxy-functionalized nanoparticle)
Implementation Method 2
binding maleinimido spacer carboxylic acid to the free amino groups in step B)
Implementation Method 3
converting the free carboxyl groups in step B) into NHS esters
Implementation Method 4
binding monomers of the protein aggregate i) to the maleinimido spacer carboxylic acids by way of a sulfhydryl group at the free end of the monomers, or ii) to the NHS esters by way of the amino group at the free end of the monomer
Data Source
AI summary
An inorganic nanoparticle is provided (step A) having the size of the aggregate of the protein misfolding disease. Free amino groups or free carboxyl groups are formed (step B) on the surface of the nanoparticle (for functionalizing the nanoparticle surface into an amine- or carboxy-functionalized nanoparticle. Maleinimido spacer carboxylic acid is bound to the free amino groups in step (B). Or, free carboxyl groups in step (B) are converted into NHS esters. Monomers of the protein aggregate are bound i) to the maleinimido spacer carboxylic acids by way of a sulfhydryl group at the free end of the monomers, or ii) to the NHS esters by way of the amino group at the free end of the monomer. A standard is provided for use in the detection of protein aggregates occurring with protein misfolding diseases.